Vertex Reschedules its Third Quarter 2012 Financial Results Conference Call and Webcast Due to Hurricane Sandy
-Company to announce third quarter financial results on Thursday, November 1, 2012-
Press Release: Vertex Pharmaceuticals Incorporated – Mon, Oct 29, 2012 9:11 AM EDT.. .
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
As a result of the effects of Hurricane Sandy and the related closure of the financial markets, Vertex Pharmaceuticals Incorporated (VRTX) today announced that it has rescheduled its third quarter 2012 earnings press release and conference call, which were originally scheduled for today, Monday, October 29. Vertex will now announce its third quarter 2012 financial results on Thursday, November 1, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT on Thursday.
The conference call will be webcast live and a link to the webcast may be accessed from the ‘Events & Presentations' page of Vertex's website at www.vrtx.com. A replay of the conference call and webcast will be archived on the company's website until November 15, 2012. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Vertex
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, Mass., we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada. Today, Vertex has more than 2,000 employees around the world, and for three years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. Vertex's press releases are available at www.vrtx.com.
VRTX – GEN
-Company to announce third quarter financial results on Thursday, November 1, 2012-
Press Release: Vertex Pharmaceuticals Incorporated – Mon, Oct 29, 2012 9:11 AM EDT.. .
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
As a result of the effects of Hurricane Sandy and the related closure of the financial markets, Vertex Pharmaceuticals Incorporated (VRTX) today announced that it has rescheduled its third quarter 2012 earnings press release and conference call, which were originally scheduled for today, Monday, October 29. Vertex will now announce its third quarter 2012 financial results on Thursday, November 1, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT on Thursday.
The conference call will be webcast live and a link to the webcast may be accessed from the ‘Events & Presentations' page of Vertex's website at www.vrtx.com. A replay of the conference call and webcast will be archived on the company's website until November 15, 2012. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Vertex
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, Mass., we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada. Today, Vertex has more than 2,000 employees around the world, and for three years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. Vertex's press releases are available at www.vrtx.com.
VRTX – GEN
Recent VRTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:20:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:17:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:14:55 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Vertex to Announce First Quarter 2026 Financial Results on May 4th • Business Wire • 04/06/2026 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:53:51 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 08:06:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 08:04:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 08:02:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 05:02:16 PM
- Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States • Business Wire • 04/01/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:10:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:03:47 PM
- Anti-Aging Protein Research Takes a Step Forward with Cell Cloning • PR Newswire (Canada) • 03/24/2026 03:05:00 PM
- Anti-Aging Protein Research Takes a Step Forward with Cell Cloning • PR Newswire (US) • 03/24/2026 03:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:04:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:11:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/13/2026 03:38:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2026 01:44:31 PM
- Vertex Shares Jump After Positive Phase 3 Kidney Drug Results • IH Market News • 03/10/2026 03:45:15 PM
- Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy • Business Wire • 03/09/2026 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:05:56 PM
- Vertex to Participate in Upcoming March Investor Conferences • Business Wire • 03/05/2026 09:00:00 PM
- Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures • Business Wire • 03/05/2026 03:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:21:16 PM

